We found that COL4A2, VWF, and IL1RN were consistent with all the training data, GEO verification data, and rat data; and the dysregulation direction of the three genes was reversed when treated with ECC-BYF III, providing direction for COPD treatment. This evidence concerns the gene COL4A2 and chronic obstructive pulmonary disease.